Question 1

How do base editing and prime editing differ in practice?

Accepted Answer

A base editor pairs an impaired Cas protein with a deaminase and converts one base into another inside a narrow activity window, which suits transition changes. A prime editor uses a nickase joined to a reverse transcriptase and writes new sequence encoded within the pegRNA, so it reaches transversions and small insertions that base editors cannot address.

Question 2

What readouts establish that an intended edit worked?

Accepted Answer

Deep amplicon sequencing of the target site remains the primary readout, reporting the fraction of reads carrying the intended change. Purity matters as much as efficiency, so analysis separates the intended conversion from bystander edits, indels and unintended byproducts. Protein-level confirmation by immunoblot or functional assay strengthens the claim where the target sequence governs a measurable phenotype.

Question 3

How should off-target activity be assessed in a thesis?

Accepted Answer

Most projects combine computational prediction of homologous sites with an unbiased genome-wide method such as a cell-free cleavage assay or an in-cell capture approach, followed by targeted deep sequencing of nominated loci. Base editors also demand attention to guide-independent activity, examined through RNA sequencing or orthogonal reporter systems rather than site-specific assays alone.

Question 4

Which delivery format suits early doctoral experiments?

Accepted Answer

Ribonucleoprotein or mRNA delivery by nucleofection is common for early work because expression is transient, which limits prolonged editor exposure and lowers background activity. Viral and lipid nanoparticle formats become relevant once the project moves toward primary cells or animal models, and each format needs its own dose response and toxicity controls.

Question 5

How is bystander editing managed and reported?

Accepted Answer

Bystander editing arises when more than one editable base sits inside the activity window. Narrowed-window editor variants, guide repositioning and choice of deaminase all reduce it, and the residual level should be reported rather than obscured. Where a bystander change is silent at the protein level, state that explicitly with supporting sequencing evidence.

Question 6

What model systems support translational claims?

Accepted Answer

Immortalised cell lines are acceptable for optimisation, but claims about therapeutic genome modification generally need patient-derived cells, induced pluripotent stem cells or primary cells carrying the variant of interest. Functional rescue in a disease-relevant assay, together with durability data across sustained culture, gives a doctoral argument far more weight than editing efficiency alone.

Biotechnology

Biotechnology

Research Frontiers in CRISPR Base Editing and Prime Editing